

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
RLL-9.2US

Total Pages in this Submission

### TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application  
P.O. Box 1450  
Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS**

and invented by:

**SUDERSHAN K. ARORA; NAWAL KISHORE**

21910 U.S. PTO  
10/611386  
07/01/03

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 09/276,368

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

### Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 60 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Larg Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
RLL-9.2US

Total Pages in this Submission

### Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets \_\_\_\_\_
- b. ☐ Informal Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☐ With Power of Attorney ☐ Without Power of Attorney
- d. ☒ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. ☐ Application Data Sheet (See 37 CFR 1.76)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Computer Readable Form (CRF)
- b. ☐ Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ Paper
- c. ☐ Statement(s) Verifying Identical Paper and Computer Readable Copy

### Accompanying Application Parts

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
13. ☒ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EV 346826189 US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Larg Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
RLL-9.2US

Total Pages in this Submission

**Accompanying Application Parts (C ntinued)**

17. ☐ Additional Enclosures *(please identify below):*

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

***Warning***

***An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.***

UTILITY PATENT APPLICATION TRANSMITTAL  
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
RLL-9.2US

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	2	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$750.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$750.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☒ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Dated: July 1, 2003



26815

CC:

PATENT TRADEMARK OFFICE

  
Signature  
GEORGE E. HEIBEL, ESQ.  
Registration N . 42,648  
CUSTOMER NUMBER: 026815

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: ARORA *et al.*

Examiner: Devesh Khare

Application No.: HEREWITH

Group Art Unit: 1623

Filing Date: HEREWITH

Divisional Application of Serial No. 09/276,368 filed March 25, 1999

For: DERIVATIVES OF MONOSACCHARIDES AS CELL  
ADHESION INHIBITORS

**STATEMENT UNDER 37 CFR § 1.63(d)(2)**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

Pursuant to 37 CFR 1.53(b)(1), inventors have been deleted in the above-identified application relative to those inventors named in the parent application as shown by the accompanying copy of the "Declaration and Power of Attorney" submitted in such parent application. Pursuant to 37 CFR § 1.63(d)(2), the following named inventors have been deleted:

**Jang Bahadur Gupta**  
**Vishwas D. Joshi**


Respectfully submitted,

ARORA *et al.*

By:   
George E. Heibel, Reg. No. 42,648

Date: July 1, 2003

Ranbaxy Laboratories Limited  
600 College Road East, Suite 2100  
Princeton, New Jersey 08540  
Tel: (609) 720-5334  
Fax: (609) 514-9779

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b> Applicant(s): <b>ARORA et al.</b>			Docket No. <b>RLL-9.2US</b>	
Serial No. <b>TBA</b>	Filing Date <b>TBA</b>	Examiner <b>TBA</b>	Group Art Unit <b>TBA</b>	
Invention: <p style="text-align: center;"><b>DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS</b></p>				
<p>I hereby certify that the following correspondence:</p> <div style="border: 1px solid black; padding: 5px; margin: 10px 0;"> <b>Utility Patent Application Transmittal (Divisional Appln); Preliminary Amendment; copy of Declaration; Patent Application (60 pages); Statement Under 37 CFR § 1.63(d)(2); Certificate of Mailing by "Express Mail", Return Postcard</b> </div> <p style="text-align: center;"><i>(Identify type of correspondence)</i></p> <p>is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on</p> <div style="margin-top: 20px;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 40%;"> <p style="text-align: center;"><u>July 1, 2003</u></p> <p style="text-align: center;"><i>(Date)</i></p> </div> <div style="width: 55%;"> <p style="text-align: center;"><b>Michelle Morgan</b></p> <p style="text-align: center;"><i>(Typed or Printed Name of Person Mailing Correspondence)</i></p> <div style="margin-top: 10px;">  </div> <p style="text-align: center;"><i>(Signature of Person Mailing Correspondence)</i></p> </div> </div> <div style="margin-top: 20px; text-align: center;"> <p><b>EV 346826189 US</b></p> <p><i>("Express Mail" Mailing Label Number)</i></p> </div> </div>				
<p><b>Note: Each paper must have its own certificate of mailing.</b></p>				